Loading...
XNASONCY
Market cap75mUSD
Dec 24, Last price  
0.98USD
1D
8.19%
1Q
8.93%
Jan 2017
-50.25%
Name

Oncolytics Biotech Inc

Chart & Performance

D1W1MN
XNAS:ONCY chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.39%
Rev. gr., 5y
%
Revenues
0k
699,756783,4560000004,851,52800000000000
Net income
-28m
L+11.75%
-12,956,120-12,781,830-14,297,524-15,642,191-17,550,2040-19,973,772-29,044,701-36,373,521-23,532,647-18,619,335-13,722,995-15,139,979-15,616,851-17,037,225-45,552,419-19,551,108-26,304,279-24,835,000-27,752,000
CFO
-28m
L+21.81%
-9,224,963-11,052,462-12,155,372-13,569,594-15,288,6320-18,033,732-22,541,183-34,255,638-24,440,533-19,676,955-15,034,830-12,477,613-14,891,318-11,920,238-19,906,124-22,068,441-22,434,009-23,355,000-28,448,000
Earnings
Mar 05, 2025

Profile

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
URL
https://www.oncolyticsbiotech.com/
IPO date
Jun 01, 2000
Employees
29
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
34,194
27,316
26,235
Unusual Expense (Income)
NOPBT
(34,194)
(27,316)
(26,235)
NOPBT Margin
Operating Taxes
97
84
49
Tax Rate
NOPAT
(34,291)
(27,400)
(26,284)
Net income
(27,752)
11.75%
(24,835)
-5.59%
(26,304)
34.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
31,620
12,574
32,912
BB yield
-34.64%
-13.29%
-44.25%
Debt
Debt current
133
216
294
Long-term debt
713
530
1,016
Deferred revenue
6,730
6,730
6,730
Other long-term liabilities
6,887
7
Net debt
(34,066)
(31,392)
(39,953)
Cash flow
Cash from operating activities
(28,448)
(23,355)
(22,434)
CAPEX
(8)
(55)
(286)
Cash from investing activities
20,222
(20,403)
(286)
Cash from financing activities
31,994
12,205
33,016
FCF
(34,286)
(25,830)
(27,841)
Balance
Cash
34,912
32,138
41,262
Long term investments
Excess cash
34,912
32,138
41,262
Stockholders' equity
(14,553)
(13,549)
(1,680)
Invested Capital
49,269
54,041
45,170
ROIC
ROCE
EV
Common stock shares outstanding
67,624
58,030
53,513
Price
1.35
-17.18%
1.63
17.27%
1.39
-41.60%
Market cap
91,292
-3.48%
94,588
27.16%
74,383
-22.52%
EV
57,226
63,196
34,431
EBITDA
(33,791)
(26,924)
(25,783)
EV/EBITDA
Interest
528
Interest/NOPBT